Reporting of atrial fibrillation with bispecific T-cell engagers in the Food and Drug Administration Adverse Event Reporting System

Clicks: 2
ID: 316512
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #140 of 143 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 143 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objective Bispecific T-cell engager (BiTE) therapies activate cytotoxic T cells and promote cytokine release, potentially increasing the risk of atrial fibrillation (AF). The atrial arrhythmic risk associated with BiTE therapy remains unclear. Methods We analyzed individual case safety reports (ICSRs) from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from the second quarter of 2014 to December 31, 2024. Reporting odds ratios (RORs) with 95% CIs and information components (ICs) with 95% credible intervals (CrIs) were used to assess whether AF was disproportionally reported with BiTE therapy as compared to all other drugs in the FAERS. We also evaluated positive (chimeric antigen receptor T-cell [CAR-T] therapy) and negative (paracetamol) control therapies. Results Analysis of 11,129,381 deduplicated ICSRs identified 14,337 cases involving BiTE therapy as a suspect drug, with 97 (0.68%) reporting AF. A signal for disproportional reporting (SDR) of AF with BiTE therapies was observed (ROR, 1.28 [95% CI, 1.04-1.57]; IC, 0.35 [95% CrI, 0.02-0.60]). Individually, epcoritamab (ROR, 2.95 [95% CI, 2.01-4.18]; IC, 1.50 [95% CrI, 0.91-1.92]) and mosunetuzumab (ROR, 3.88 [95% CI, 1.92-7.01]; IC, 1.76 [95% CrI, 0.74-2.46]) were associated with SDRs. No other BiTE therapy showed an SDR. CAR-T therapy, the positive control, showed an SDR for AF (ROR, 2.40 [95% CI, 2.05-2.79]; IC, 1.24 [95% CrI, 0.99-1.42]). In contrast, the negative control, paracetamol, did not. Conclusion AF appears to be disproportionally reported with BiTE therapy in the FAERS. This association warrants further investigation.
Reference Key
openalex_W7164008656 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Brian Portela, Osama Abdelghany, Craig I Coleman
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag168
URL
https://doi.org/10.1093/ajhp/zxag168
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.